Credit: Getty Images. Researchers evaluated liver test abnormalities in patients hospitalized with COVID-19 and assessed cytokine levels in individuals with vs without abnormal test results.

Biotech Orpheris has been given the FDA go-ahead for a phase 2 aimed at calming the cytokine storm sometimes caused by COVID-19. The biotech hopes its therapy can help those with the disease who are ...

LOS ANGELES & CHICAGO--(BUSINESS WIRE)--Professor Frederick Behm, Head of the University of Illinois College of Medicine at Chicago Department of Pathology, and Dr. Bruce Gillis, CEO of EpicGenetics, ...

BOULDER, Colo., June 15, 2020 /PRNewswire/ -- MBio Diagnostics today announced delivery to the U.S. Department of Defense with funding for this effort provided by the Defense Health Program through ...

A big flush of funding from the National Institute for Health Research (NIHR) in the United Kingdom is pushing new research on ways to diagnose and treat long COVID. A University of Cambridge team ...

Researchers have identified a blood profile that could help identify COVID-19 patients at greatest risk of deterioration and direct them towards trials of specific treatments that could modify their ...

CLEVELAND, Ohio — Weathering the “cytokine storm” could be one of the keys in saving severely ill coronavirus patients, but doctors still don’t know all the facts about the extreme inflammatory ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--ImmusanT, Inc., a clinical-stage company developing Nexvax2®, a therapeutic vaccine being investigated to protect against the effects of gluten in HLA-DQ2.5+ ...

Goal is to advance new combined blood purification technologies to treat Gram negative sepsis – a deadly global killer PRINCETON, N.J., Oct. 31, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: ...